Latest Healthcare News

Oceania Healthcare has modernized its property portfolio and updated its dividend policy to align with a new strategic direction under CEO Suzanne Dvorak, aiming to meet New Zealand's growing aged care demand.

Atomo Diagnostics has successfully closed a Share Purchase Plan and secured shareholder approval for a Tranche 2 Placement, raising a combined $1.53 million to support its ongoing operations.

Orthocell has marked a pivotal milestone with the first US surgical use of its Remplir™ nerve repair device following FDA clearance, setting the stage for commercial expansion in a $1.6 billion market.

Adherium Limited has successfully closed the institutional portion of its entitlement offer, increasing the raise to $4.492 million due to robust demand. The company now invites retail shareholders to participate as it advances its digital respiratory health solutions.

Opyl Limited has taken a bold step into digital assets by acquiring approximately 2 Bitcoin and securing a $2 million finance facility backed by these holdings, signaling a strategic pivot towards blockchain integration in healthcare technology.

Singular Health Group has completed a $7.85 million capital raising through a new share issue, alongside additional funds from option exercises, strengthening its financial position for growth in medical imaging technology.

Cleo Diagnostics has gained approval to access the prestigious PLCO biobank, a move set to strengthen its FDA submission and accelerate development of its ovarian cancer diagnostic tests.

ParagonCare appoints Carmen Riley as CEO effective July 1, 2025, with a planned transition period under outgoing CEO David Collins to complete integration and pursue M&A opportunities.

HealthCo Healthcare & Wellness REIT reports a $1.483 billion portfolio valuation, down 4.3% due to cap rate shifts, while suspending its Q2 distribution to safeguard liquidity amid ongoing hospital asset due diligence.

Adherium Limited is raising up to $4 million through a partially underwritten entitlement offer to expand its US digital health platform and recruit key personnel. The capital raise supports scaling patient onboarding and advancing its FDA-cleared smart inhaler technology.

Radiopharm Theranostics has inked a clinical supply agreement with Cyclotek to support its Phase 1 trial of RAD 402, a novel radiotherapeutic targeting prostate cancer, set to commence in Australia in late 2025.

Rhythm Biosciences has regained NATA accreditation for its geneType laboratory, a key step toward commercialising its ColoSTAT® cancer risk test as an in-house diagnostic.